NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 5.07 against a street estimate of 8.40 — a miss of 39.6%.
with an average price target of ₹197.00.
| Document | Date |
|---|---|
| Q1 FY27 earnings call IOL CHEMICALS AND PHARMACEUTICALS LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Revenue from operations: INR 756 crores (Q1 FY27) vs IN | 2026-08-20 |
| Investor presentation · Q1 FY27 IOL CHEMICALS AND PHARMACEUTICALS LIMITED INVESTOR SUMMARY – Q1 FY27 --- HEADLINE NUMBERS • Q1 FY27 Revenue from Operations: ₹756.3 Cr (up 37.1% Yo | 2026-08-12 |
| Quarterly results · Q1 FY27 IOL CHEMICALS & PHARMACEUTICALS LTD – Q1 FY27 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹756.3 Cr (Q1 FY27) – highest-ever quarter | 2026-08-10 |
| Annual report FY2026 IOL CHEMICALS AND PHARMACEUTICALS LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue & Profitability: Strong growth in revenue and profitabilit | 2026-08-07 |
| Q4 FY26 earnings call IOL CHEMICALS AND PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 revenue from operations: INR 619 crores (vs INR 528 crores in | 2026-05-28 |
| Investor presentation · Q4 FY26 IOL CHEMICALS AND PHARMACEUTICALS LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue from Operations: ₹2,319.1 Cr (up 11.5% YoY fr | 2026-05-21 |
| Quarterly results · Q4 FY26 IOL CHEMICALS & PHARMACEUTICALS LTD – FINANCIAL RESULTS SUMMARY Q4 & FY26 (Year ended 31st March 2026) --- HEADLINE NUMBERS • Q4 FY26 Revenue from | 2026-05-20 |
| Quarterly results | 2026-03-17 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Feb 17, 2026 | 2026-02-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for IOL Chemicals and Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.